The Associations of Cerebrospinal Fluid Biomarkers with Cognition, and Rapid Eye Movement Sleep Behavior Disorder in Early Parkinson's Disease

Overview

Journal Front Neurosci

Date 2022 Dec 12

PMID 36507360

Authors

Mingzhu Tao

Kaixin Dou

Yijie Xie

Binghui Hou

Anmu Xie

Affiliations

Soon will be listed here.

Abstract

Background: In Parkinson's disease (PD), levels of cerebrospinal fluid (CSF) biomarkers and progression of non-motor symptoms are associated, but the specifics are not yet clear.

Objective: The aim of this study was to investigate the associations of non-motor symptoms with CSF biomarkers in PD.

Materials And Methods: We assessed 487 individuals from the Parkinson's Progression Markers Initiative (PPMI), consisting of 155 healthy controls (HCs) and 332 individuals with PD. Patients with PD were grouped according to non-motor symptoms and compared CSF α-synuclein (α-syn), amyloid-beta 1-42 (Aβ), and total tau (t-tau) levels. Multiple linear regressions were used in baseline analysis and linear mixed-effects models in longitudinal analysis. Analyses of mediating effects between cognition and CSF biomarkers were also performed.

Results: At baseline, PD patients with cognitive impairment (PDCI) exhibited significantly lower CSF α-syn (β = -0.1244; = 0.0469), Aβ (β = -0.1302; = 0.0447), and t-tau (β = -0.1260; = 0.0131) levels than PD patients without cognitive impairment (PDCU). Moreover, a faster decline of α-syn (β = -0.2152; = 0.0374) and Aβ (β = -0.3114; = 0.0023) and a faster rise of t-tau (β = -0.1534; = 0.0274) have been found in longitudinal analysis. The Aβ positive group showed an earlier decline in cognitive performance (β = -0.5341; = 0.0180) compared with the negative Aβ group in both analyses. In addition, we found that PD patients with probable rapid eye movement sleep behavior disorder (pRBD) showed decreased CSF α-syn (β = -0.1343; = 0.0033) levels. Finally, mediation analysis demonstrated that olfactory function partially mediated the relationship between cognition and CSF biomarkers levels.

Conclusion: Our study shows that CSF biomarkers are associated with cognition at baseline and longitudinally. Cognitive impairment is more severe in patients with a heavier Aβ burden. CSF α-syn decreased in PD patients with pRBD. This study suggests that early recognition of the increased risk of non-motor symptoms is important for disease surveillance and may be associated with the pathological progression of CSF markers.

Citing Articles

The α-Synuclein Seeding Amplification Assay for Parkinson's Disease.

Yi L, Tan E, Zhou Z Int J Mol Sci. 2025; 26(1.

PMID: 39796243 PMC: 11720040. DOI: 10.3390/ijms26010389.

Machine Learning for Early Detection of Cognitive Decline in Parkinson's Disease Using Multimodal Biomarker and Clinical Data.

Mohammadi R, Ng S, Tan J, Ng A, Deng X, Choi X Biomedicines. 2025; 12(12.

PMID: 39767666 PMC: 11674004. DOI: 10.3390/biomedicines12122758.

An interactive web application to identify early Parkinsonian non-tremor-dominant subtypes.

Xu X, Gu W, Shen X, Liu Y, Zhai S, Xu C J Neurol. 2024; 271(4):2010-2018.

PMID: 38175296 DOI: 10.1007/s00415-023-12156-5.

References

Williams-Gray C, Foltynie T, Brayne C, Robbins T, Barker R . Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain. 2007; 130(Pt 7):1787-98. DOI: 10.1093/brain/awm111. View

Levy G, Tang M, Louis E, Cote L, Alfaro B, Mejia H . The association of incident dementia with mortality in PD. Neurology. 2002; 59(11):1708-13. DOI: 10.1212/01.wnl.0000036610.36834.e0. View

Attems J, Walker L, Jellinger K . Olfactory bulb involvement in neurodegenerative diseases. Acta Neuropathol. 2014; 127(4):459-75. DOI: 10.1007/s00401-014-1261-7. View

Clinton L, Blurton-Jones M, Myczek K, Trojanowski J, LaFerla F . Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010; 30(21):7281-9. PMC: 3308018. DOI: 10.1523/JNEUROSCI.0490-10.2010. View

Aarsland D, Andersen K, Larsen J, Lolk A, Kragh-Sorensen P . Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003; 60(3):387-92. DOI: 10.1001/archneur.60.3.387. View

Mollenhauer B, Trenkwalder C, von Ahsen N, Bibl M, Steinacker P, Brechlin P . Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord. 2006; 22(3):200-8. DOI: 10.1159/000094871. View

Morley J, Xie S, Hurtig H, Stern M, Colcher A, Horn S . Genetic influences on cognitive decline in Parkinson's disease. Mov Disord. 2012; 27(4):512-8. PMC: 3323737. DOI: 10.1002/mds.24946. View

Aarsland D, Andersen K, Larsen J, Lolk A, Nielsen H, Kragh-Sorensen P . Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology. 2001; 56(6):730-6. DOI: 10.1212/wnl.56.6.730. View

Bohnen N, Muller M . In vivo neurochemical imaging of olfactory dysfunction in Parkinson's disease. J Neural Transm (Vienna). 2012; 120(4):571-6. PMC: 3612386. DOI: 10.1007/s00702-012-0956-y. View

10.

Heywood W, Galimberti D, Bliss E, Sirka E, Paterson R, Magdalinou N . Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegener. 2015; 10:64. PMC: 4666172. DOI: 10.1186/s13024-015-0059-y. View

11.

Lin C, Wu R . Biomarkers of cognitive decline in Parkinson's disease. Parkinsonism Relat Disord. 2015; 21(5):431-43. DOI: 10.1016/j.parkreldis.2015.02.010. View

12.

Popescu A, Lippa C, Lee V, Trojanowski J . Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol. 2004; 61(12):1915-9. DOI: 10.1001/archneur.61.12.1915. View

13.

Nomura T, Inoue Y, Kagimura T, Uemura Y, Nakashima K . Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson's disease patients. Sleep Med. 2011; 12(7):711-3. DOI: 10.1016/j.sleep.2011.01.015. View

14.

Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K . Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004; 318(1):121-34. DOI: 10.1007/s00441-004-0956-9. View

15.

Shaw L, Hansson O, Manuilova E, Masters C, Doecke J, Li Q . Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS. Clin Biochem. 2019; 72:7-14. DOI: 10.1016/j.clinbiochem.2019.05.006. View

16.

Compta Y, Pereira J, Rios J, Ibarretxe-Bilbao N, Junque C, Bargallo N . Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat Disord. 2013; 19(8):717-24. DOI: 10.1016/j.parkreldis.2013.03.009. View

17.

Bereczki E, Francis P, Howlett D, Pereira J, Hoglund K, Bogstedt A . Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. Alzheimers Dement. 2016; 12(11):1149-1158. DOI: 10.1016/j.jalz.2016.04.005. View

18.

Aarsland D, Kurz M . The epidemiology of dementia associated with Parkinson disease. J Neurol Sci. 2009; 289(1-2):18-22. DOI: 10.1016/j.jns.2009.08.034. View

19.

Mollenhauer B, Caspell-Garcia C, Coffey C, Taylor P, Singleton A, Shaw L . Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease. Mov Disord. 2019; 34(9):1354-1364. PMC: 7098385. DOI: 10.1002/mds.27806. View

20.

Hobson P, Meara J . Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord. 2004; 19(9):1043-9. DOI: 10.1002/mds.20216. View